Revelation Biosciences, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 2.63 million compared to USD 1.17 million a year ago. Basic loss per share from continuing operations was USD 12.6 compared to USD 57.3 a year ago. Diluted loss per share from continuing operations was USD 12.6 compared to USD 57.3 a year ago.
For the nine months, net income was USD 2.08 million compared to net loss of USD 9.62 million a year ago. Basic earnings per share from continuing operations was USD 12.9 compared to basic loss per share from continuing operations of USD 588.3001 a year ago. Diluted earnings per share from continuing operations was USD 12.3 compared to diluted loss per share from continuing operations of USD 588.3001 a year ago.